Skip to main content
Top
Published in: BMC Public Health 1/2010

Open Access 01-12-2010 | Research article

HCV co-infection in HIV positive population in British Columbia, Canada

Authors: Jane A Buxton, Amanda Yu, Paul H Kim, John J Spinelli, Margot Kuo, Maria Alvarez, Mark Gilbert, Mel Krajden

Published in: BMC Public Health | Issue 1/2010

Login to get access

Abstract

Background

As HIV and hepatitis C (HCV) share some modes of transmission co-infection is not uncommon. This study used a population-based sample of HIV and HCV tested individuals to determine the prevalence of HIV/HCV co-infection, the sequence of virus diagnoses, and demographic and associated risk factors.

Methods

Positive cases of HIV were linked to the combined laboratory database (of negative and positive HCV antibody results) and HCV reported cases in British Columbia (BC).

Results

Of 4,598 HIV cases with personal identifiers, 3,219 (70%) were linked to the combined HCV database, 1,700 (53%) of these were anti-HCV positive. HCV was diagnosed first in 52% of co-infected cases (median time to HIV identification 3 1/2 years). HIV and HCV was diagnosed within a two week window in 26% of cases. Among individuals who were diagnosed with HIV infection at baseline, subsequent diagnoses of HCV infection was independently associated with: i) intravenous drug use (IDU) in males and females, Hazard Ratio (HR) = 6.64 (95% CI: 4.86-9.07) and 9.76 (95% CI: 5.76-16.54) respectively; ii) reported Aboriginal ethnicity in females HR = 2.09 (95% CI: 1.34-3.27) and iii) males not identified as men-who-have-sex-with-men (MSM), HR = 2.99 (95% CI: 2.09-4.27).
Identification of HCV first compared to HIV first was independently associated with IDU in males and females OR = 2.83 (95% CI: 1.84-4.37) and 2.25 (95% CI: 1.15-4.39) respectively, but not Aboriginal ethnicity or MSM. HIV was identified first in 22%, with median time to HCV identification of 15 months;

Conclusion

The ability to link BC public health and laboratory HIV and HCV information provided a unique opportunity to explore demographic and risk factors associated with HIV/HCV co-infection. Over half of persons with HIV infection who were tested for HCV were anti-HCV positive; half of these had HCV diagnosed first with HIV identification a median 3.5 years later. This highlights the importance of public health follow-up and harm reduction measures for people identified with HCV to prevent subsequent HIV infection.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, Yoshida E, Renner E, Wong P, Deschenes M: Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol. 2007, 21 (Suppl C): 25C-34C.CrossRefPubMedPubMedCentral Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, Yoshida E, Renner E, Wong P, Deschenes M: Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol. 2007, 21 (Suppl C): 25C-34C.CrossRefPubMedPubMedCentral
3.
go back to reference Wood E, Kerr T, Stoltz J, Qui Z, Zhang R, Montaner JS, Tyndall MW: Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facility. Public Health. 2005, 119: 1111-1115. 10.1016/j.puhe.2005.05.006.CrossRefPubMed Wood E, Kerr T, Stoltz J, Qui Z, Zhang R, Montaner JS, Tyndall MW: Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facility. Public Health. 2005, 119: 1111-1115. 10.1016/j.puhe.2005.05.006.CrossRefPubMed
4.
go back to reference Miller CL, Wood E, Spittal PM, Li K, Frankish JC, Braitstein P, Montaner JS, Schechter MT: The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. J Acquir Immune Defic Syndr. 2004, 36: 743-749. 10.1097/00126334-200406010-00012.CrossRefPubMed Miller CL, Wood E, Spittal PM, Li K, Frankish JC, Braitstein P, Montaner JS, Schechter MT: The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. J Acquir Immune Defic Syndr. 2004, 36: 743-749. 10.1097/00126334-200406010-00012.CrossRefPubMed
5.
go back to reference Sulkowski MS, Thomas DL: Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness. AIDS. 2005, 19 (Suppl 3): S8-12. 10.1097/01.aids.0000192064.09281.48.CrossRefPubMed Sulkowski MS, Thomas DL: Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness. AIDS. 2005, 19 (Suppl 3): S8-12. 10.1097/01.aids.0000192064.09281.48.CrossRefPubMed
6.
go back to reference Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, Torre-Cisneros J, Andrade RJ, Gonzalez-Serrano M, Aguilar J, Aguilar-Guisado M, Navarro JM, Salmerón J, Caballero-Granado FJ, García-García JA: HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005, 41: 779-789. 10.1002/hep.20626.CrossRefPubMed Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, Torre-Cisneros J, Andrade RJ, Gonzalez-Serrano M, Aguilar J, Aguilar-Guisado M, Navarro JM, Salmerón J, Caballero-Granado FJ, García-García JA: HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005, 41: 779-789. 10.1002/hep.20626.CrossRefPubMed
7.
go back to reference Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, Morsica G, Pizzaferri P, Ladisa N, Sighinolfi L, Chiodera A, Solmone M, Lalle E, Ippolito G, Monforte A, HepaICoNA Study Group, ICoNA Study Group: Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals. Antivir Ther. 2005, 10: 109-117.PubMed Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, Morsica G, Pizzaferri P, Ladisa N, Sighinolfi L, Chiodera A, Solmone M, Lalle E, Ippolito G, Monforte A, HepaICoNA Study Group, ICoNA Study Group: Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals. Antivir Ther. 2005, 10: 109-117.PubMed
8.
go back to reference Carter M: HCV coinfection hastens HIV disease progression. IAPAC Mon. 2004, 10: 433-PubMed Carter M: HCV coinfection hastens HIV disease progression. IAPAC Mon. 2004, 10: 433-PubMed
9.
go back to reference Hershow RC, O'Driscoll PT, Handelsman E, Pitt J, Hillyer G, Serchuck L, Lu M, Chen KT, Yawetz S, Pacheco S, Davenny K, Adeniyi-Jones S, Thomas DL: Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. Clin Infect Dis. 2005, 40: 859-867. 10.1086/428121.CrossRefPubMed Hershow RC, O'Driscoll PT, Handelsman E, Pitt J, Hillyer G, Serchuck L, Lu M, Chen KT, Yawetz S, Pacheco S, Davenny K, Adeniyi-Jones S, Thomas DL: Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. Clin Infect Dis. 2005, 40: 859-867. 10.1086/428121.CrossRefPubMed
10.
go back to reference Rodriguez B, Bobak DA: Management of Hepatitis C in HIV-infected Patients. Curr Infect Dis Rep. 2005, 7: 91-102. 10.1007/s11908-005-0067-0.CrossRefPubMed Rodriguez B, Bobak DA: Management of Hepatitis C in HIV-infected Patients. Curr Infect Dis Rep. 2005, 7: 91-102. 10.1007/s11908-005-0067-0.CrossRefPubMed
11.
go back to reference Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, Moreno L, Antela A, Perez-Elias MJ, Dronda F, Marín A, Hernandez-Ranz F, Moreno A, Moreno S: Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2005, 40: 588-593. 10.1086/427216.CrossRefPubMed Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, Moreno L, Antela A, Perez-Elias MJ, Dronda F, Marín A, Hernandez-Ranz F, Moreno A, Moreno S: Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2005, 40: 588-593. 10.1086/427216.CrossRefPubMed
12.
go back to reference Fuster D, Planas R, Muga R, Ballesteros AL, Santos J, Tor J, Sirera G, Guardiola H, Salas A, Cabre E, Ojanguren I, Barluenga E, Rey-Joly C, Clotet B, Tural C: Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses. 2004, 20: 1293-1297. 10.1089/aid.2004.20.1293.CrossRefPubMed Fuster D, Planas R, Muga R, Ballesteros AL, Santos J, Tor J, Sirera G, Guardiola H, Salas A, Cabre E, Ojanguren I, Barluenga E, Rey-Joly C, Clotet B, Tural C: Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses. 2004, 20: 1293-1297. 10.1089/aid.2004.20.1293.CrossRefPubMed
13.
go back to reference Cote P, Baril JG, Hebert MN, Klein M, Lalonde R, Poliquin M, Rouleau D, Therrien R, Vezina S, Willems B, Dion H, Junod P, Lapointe N, Lévesque D, Pinault L, Tremblay C, Trottier B, Trottier S, Tsoukas C, Piché A: Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals. Can J Infect Dis Med Microbiol. 2007, 18: 293-303.PubMedPubMedCentral Cote P, Baril JG, Hebert MN, Klein M, Lalonde R, Poliquin M, Rouleau D, Therrien R, Vezina S, Willems B, Dion H, Junod P, Lapointe N, Lévesque D, Pinault L, Tremblay C, Trottier B, Trottier S, Tsoukas C, Piché A: Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals. Can J Infect Dis Med Microbiol. 2007, 18: 293-303.PubMedPubMedCentral
14.
go back to reference Lee W, Dieterich D: Challenges in the management of HIV and hepatitis C virus co-infection. Drugs. 2004, 64: 693-700. 10.2165/00003495-200464070-00002.CrossRefPubMed Lee W, Dieterich D: Challenges in the management of HIV and hepatitis C virus co-infection. Drugs. 2004, 64: 693-700. 10.2165/00003495-200464070-00002.CrossRefPubMed
15.
go back to reference Plosker GL, Keating GM: Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection. Drugs. 2004, 64: 2823-2843. 10.2165/00003495-200464240-00009.CrossRefPubMed Plosker GL, Keating GM: Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection. Drugs. 2004, 64: 2823-2843. 10.2165/00003495-200464240-00009.CrossRefPubMed
16.
go back to reference Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J, Pedreira J: Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol. 1999, 31 (Suppl 1): 119-123. 10.1016/S0168-8278(99)80387-0.CrossRefPubMed Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J, Pedreira J: Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol. 1999, 31 (Suppl 1): 119-123. 10.1016/S0168-8278(99)80387-0.CrossRefPubMed
17.
go back to reference Bonacini M, Puoti M: Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med. 2000, 160: 3365-3373. 10.1001/archinte.160.22.3365.CrossRefPubMed Bonacini M, Puoti M: Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med. 2000, 160: 3365-3373. 10.1001/archinte.160.22.3365.CrossRefPubMed
18.
go back to reference Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM: Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis. 1999, 179: 1254-1258. 10.1086/314720.CrossRefPubMed Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM: Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis. 1999, 179: 1254-1258. 10.1086/314720.CrossRefPubMed
19.
go back to reference Benhamou Y, Bochet M, Di MV, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999, 30: 1054-1058. 10.1002/hep.510300409.CrossRefPubMed Benhamou Y, Bochet M, Di MV, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999, 30: 1054-1058. 10.1002/hep.510300409.CrossRefPubMed
20.
go back to reference Cacoub P: Treatment of hepatitis C in HIV/hepatitis C co-infected patients: what is the evidence?. Int J STD AIDS. 2005, 16: 1-4. 10.1258/0956462052932737.CrossRefPubMed Cacoub P: Treatment of hepatitis C in HIV/hepatitis C co-infected patients: what is the evidence?. Int J STD AIDS. 2005, 16: 1-4. 10.1258/0956462052932737.CrossRefPubMed
21.
go back to reference Romero M, Perez-Olmeda M, Garcia-Samaniego J, Soriano V: Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations. Drug Saf. 2004, 27: 7-24. 10.2165/00002018-200427010-00002.CrossRefPubMed Romero M, Perez-Olmeda M, Garcia-Samaniego J, Soriano V: Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations. Drug Saf. 2004, 27: 7-24. 10.2165/00002018-200427010-00002.CrossRefPubMed
22.
go back to reference Sulkowski MS, Thomas DL: Hepatitis C in the HIV-infected patient. Clin Liver Dis. 2003, 7: 179-194. 10.1016/S1089-3261(02)00074-0.CrossRefPubMed Sulkowski MS, Thomas DL: Hepatitis C in the HIV-infected patient. Clin Liver Dis. 2003, 7: 179-194. 10.1016/S1089-3261(02)00074-0.CrossRefPubMed
23.
go back to reference Maheshwari A, Ray S, Thuluvath PJ: Acute hepatitis C. Lancet. 2008, 372: 321-32. 10.1016/S0140-6736(08)61116-2.CrossRefPubMed Maheshwari A, Ray S, Thuluvath PJ: Acute hepatitis C. Lancet. 2008, 372: 321-32. 10.1016/S0140-6736(08)61116-2.CrossRefPubMed
24.
go back to reference Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH: Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000, 132: 296-305.CrossRefPubMed Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH: Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000, 132: 296-305.CrossRefPubMed
25.
go back to reference Cooper C: HAART and Liver: a discussion of hepatic disease in those living with HIV. Interview by Paul C Adams. Can J Gastroenterol. 2008, 22: 973-975.CrossRefPubMedPubMedCentral Cooper C: HAART and Liver: a discussion of hepatic disease in those living with HIV. Interview by Paul C Adams. Can J Gastroenterol. 2008, 22: 973-975.CrossRefPubMedPubMedCentral
26.
go back to reference Bodsworth NJ, Cunningham P, Kaldor J, Donovan B: Hepatitis C virus infection in a large cohort of homosexually active men: independent associations with HIV-1 infection and injecting drug use but not sexual behaviour. Genitourin Med. 1996, 72: 118-122.PubMedPubMedCentral Bodsworth NJ, Cunningham P, Kaldor J, Donovan B: Hepatitis C virus infection in a large cohort of homosexually active men: independent associations with HIV-1 infection and injecting drug use but not sexual behaviour. Genitourin Med. 1996, 72: 118-122.PubMedPubMedCentral
27.
go back to reference Myers T, Allman D, Xu K, Remis RS, Aguinaldo J, Burchell A, Calzavara L, Swantee C: The prevalence and correlates of hepatitis C virus (HCV) infection and HCV-HIV co-infection in a community sample of gay and bisexual men. Int J Infect Dis. 2009, 13: 730-9. 10.1016/j.ijid.2008.11.015.CrossRefPubMed Myers T, Allman D, Xu K, Remis RS, Aguinaldo J, Burchell A, Calzavara L, Swantee C: The prevalence and correlates of hepatitis C virus (HCV) infection and HCV-HIV co-infection in a community sample of gay and bisexual men. Int J Infect Dis. 2009, 13: 730-9. 10.1016/j.ijid.2008.11.015.CrossRefPubMed
28.
go back to reference Urbanus AT, Laar van de TJ, Stolte IG, Schinkel J, Heijman T, Coutinho RA, Prins M: Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS. 2009, 23: F1-F7. 10.1097/QAD.0b013e32832e5631.CrossRefPubMed Urbanus AT, Laar van de TJ, Stolte IG, Schinkel J, Heijman T, Coutinho RA, Prins M: Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS. 2009, 23: F1-F7. 10.1097/QAD.0b013e32832e5631.CrossRefPubMed
29.
go back to reference Pelgrom JM, Vogelaers D, Colle I: Hepatitis C-seroconversion within three to six months after having contracted clinical syphilis and/or lymphogranuloma venereum rectitis in five homosexually active, HIV seropositive men. Acta Clin Belg. 2008, 63: 335-338.CrossRefPubMed Pelgrom JM, Vogelaers D, Colle I: Hepatitis C-seroconversion within three to six months after having contracted clinical syphilis and/or lymphogranuloma venereum rectitis in five homosexually active, HIV seropositive men. Acta Clin Belg. 2008, 63: 335-338.CrossRefPubMed
30.
go back to reference Gotz HM, van Doornum G, Niesters HG, den Hollander JG, Thio HB, de Zwart O: A cluster of acute hepatitis C virus infection among men who have sex with men--results from contact tracing and public health implications. AIDS. 2005, 19: 969-974. 10.1097/01.aids.0000171412.61360.f8.CrossRefPubMed Gotz HM, van Doornum G, Niesters HG, den Hollander JG, Thio HB, de Zwart O: A cluster of acute hepatitis C virus infection among men who have sex with men--results from contact tracing and public health implications. AIDS. 2005, 19: 969-974. 10.1097/01.aids.0000171412.61360.f8.CrossRefPubMed
31.
go back to reference Van Den BC, Smit C, Van Brussel G, Coutinho R, Prins M: Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007, 102: 1454-1462. 10.1111/j.1360-0443.2007.01912.x.CrossRef Van Den BC, Smit C, Van Brussel G, Coutinho R, Prins M: Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007, 102: 1454-1462. 10.1111/j.1360-0443.2007.01912.x.CrossRef
Metadata
Title
HCV co-infection in HIV positive population in British Columbia, Canada
Authors
Jane A Buxton
Amanda Yu
Paul H Kim
John J Spinelli
Margot Kuo
Maria Alvarez
Mark Gilbert
Mel Krajden
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2010
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-10-225

Other articles of this Issue 1/2010

BMC Public Health 1/2010 Go to the issue